FDA: Breast Implants, ALCL Cancer Link Still Concerning



[ad_1]

People who have breast implants are at risk of developing large cell anaplastic lymphoma (ALCL), a rare cancer that can spread throughout the body, according to the FDA, the US Food and Drug Administration.

While the FDA had identified the link between breast implants and cancer in 2011, a new report from NBC News highlights the fact that manufacturers are not planning to stop producing the implants in question. This is despite the fact that the FDA has received more than 400 reports from patients who have developed ALCL, nine of whom have died.

Specifically, it is the so-called textured version of implants that, according to the FDA, could be more likely to cause an ALCL, as opposed to those with a smooth surface. But regardless of the type of surface, the FDA claims that both breast implant versions are linked to an increased risk of developing cancer.

Allergen and Mentor are two companies that manufacture textured breast implants. The mentor refers to the FDA warning on his own website. And through spokespersons, the two companies indicated that, although it is not planned to stop production, doctors should inform all patients receiving implants of possible cancer risks, as well as signs before – LALC runners.

Despite its link with breast implants, it is important to understand that ALCL is not breast cancer. Rather, it is a rare cancer of the blood, a non-Hodgkin's lymphoma. The World Health Organization (WHO) has noted that since the discovery of ALCL (BIA-ALCL) associated with breast implants more than 20 years ago, implants filled with saline and silicone have been implicated in the development of breast implants. risk of developing an ALCI.

[ad_2]
Source link